439 related articles for article (PubMed ID: 29908325)
1. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
2. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
[TBL] [Abstract][Full Text] [Related]
5. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
Elife; 2020 Oct; 9():. PubMed ID: 33006315
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.
Mercatelli D; Bolognesi P; Frassineti M; Pisanò CA; Longo F; Shimshek DR; Morari M
Pharmacol Res Perspect; 2019 Jun; 7(3):e00484. PubMed ID: 31149340
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
[TBL] [Abstract][Full Text] [Related]
8. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum.
Centonze D; Gubellini P; Usiello A; Rossi S; Tscherter A; Bracci E; Erbs E; Tognazzi N; Bernardi G; Pisani A; Calabresi P; Borrelli E
Neuroscience; 2004; 129(1):157-66. PubMed ID: 15489038
[TBL] [Abstract][Full Text] [Related]
9. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission.
Tozzi A; Tscherter A; Belcastro V; Tantucci M; Costa C; Picconi B; Centonze D; Calabresi P; Borsini F
Neuropharmacology; 2007 Nov; 53(6):783-9. PubMed ID: 17889039
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
[TBL] [Abstract][Full Text] [Related]
11. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
12. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
13. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice.
Cepeda C; Hurst RS; Altemus KL; Flores-Hernández J; Calvert CR; Jokel ES; Grandy DK; Low MJ; Rubinstein M; Ariano MA; Levine MS
J Neurophysiol; 2001 Feb; 85(2):659-70. PubMed ID: 11160501
[TBL] [Abstract][Full Text] [Related]
14. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
Kadgien CA; Kamesh A; Milnerwood AJ
Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
[TBL] [Abstract][Full Text] [Related]
15. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
Skiteva O; Yao N; Sitzia G; Chergui K
J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
[TBL] [Abstract][Full Text] [Related]
17. Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice.
Sitzia G; Skiteva O; Chergui K
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358985
[TBL] [Abstract][Full Text] [Related]
18. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice.
Tong Y; Pisani A; Martella G; Karouani M; Yamaguchi H; Pothos EN; Shen J
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14622-7. PubMed ID: 19667187
[TBL] [Abstract][Full Text] [Related]
19. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
